SLI-F06, a novel FMOD-derived peptide, significantly improves scar appearance and tensile strength in preclinical wound healing models.
Background
<b>Scarring</b> and <b>cutaneous fibrosis</b> present significant functional and aesthetic challenges, yet no drugs are specifically approved to prevent or reduce them. Current therapeutic approaches are limited by efficacy and safety concerns. Fibromodulin (FMOD) has shown promise by modulating adult dermal fibroblasts to adopt fetal-like characteristics, improving wound appearance and tensile strength. However, producing FMOD from mammalian cells is expensive, variable, and raises safety concerns, creating a need for a more practical alternative. This gap led to the development of SLI-F06.
Study Design
Researchers conducted comprehensive preclinical studies across multiple animal models, including mice, rats, Yorkshire pigs (modeling normal human wound healing), and red Duroc pigs (mimicking human proliferative and hypertrophic scarring). The studies evaluated the efficacy of <b>SLI-F06</b> on scar appearance, tensile strength, and histological outcomes. Additionally, extensive safety assessments, including genotoxicity and local/systemic toxicity, were performed to meet FDA Investigational New Drug application requirements. A specialized formulation buffer was also developed to ensure SLI-F06 stability.
Results
<b>SLI-F06</b> demonstrated significant improvements in scar appearance, tensile strength tests, and histological outcomes across all tested animal models, including mice, rats, Yorkshire pigs, and red Duroc pigs. The novel peptide successfully retained the essential properties of native FMOD, specifically promoting cell migration, increasing tensile strength, and stimulating antifibrotic effects. Crucially, comprehensive safety studies, conducted to meet FDA Investigational New Drug application requirements, revealed no evidence of genotoxicity or local or systemic toxicity. A specialized formulation buffer was also successfully developed, ensuring the stability of
SLI-F06for clinical use after refrigeration. These findings collectively support the preclinical efficacy and safety profile ofSLI-F06as a promising therapeutic agent for <b>cutaneous wound healing</b>.
Key Findings
- SLI-F06 significantly improved scar appearance and tensile strength in multiple animal wound healing models.
- The peptide demonstrated antifibrotic effects and promoted cell migration, retaining FMOD's essential properties.
- SLI-F06 exhibited no genotoxicity or local/systemic toxicity in extensive FDA-required safety studies.
- A stable formulation buffer for SLI-F06 was successfully developed for potential clinical use.
Why It Matters
<b>SLI-F06 offers a novel, potentially first-in-class therapeutic option for preventing and reducing scarring</b>, addressing a critical unmet medical need. Its chemically synthesized nature overcomes the high costs, variability, and safety concerns associated with mammalian cell-derived FMOD, paving the way for more consistent and accessible treatment. The successful development of a stable formulation buffer and the demonstration of a clean safety profile, meeting FDA IND requirements, significantly de-risk its clinical translation. This peptide could fundamentally change how <b>cutaneous wound healing</b> is managed, moving beyond current limited options to a targeted, antifibrotic approach.
sli-f06
fmod
scarring
wound-healing
fibrosis
preclinical